gardasil vaccine china

China, Merck and Gardasil

Merck shares plunge as company pauses Gardasil vaccine shipments in China, hurting 2025 outlook

Merck's full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 billion.

The Associated Press - Busines… · 17h

Merck 2025 sales forecast underwhelms as it pauses Gardasil sales in China

Shares of Merck slid Tuesday after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales forecast due partly to a pause in shipments of one of its top-selling products to China. The drugmaker plans to temporarily pause shipments of its Gardasil vaccine to China at least through the middle of the year.

YAHOO!Finance · 18h

Merck's Gardasil Vaccine Slowdown In China Bites Again, Stock Falls On Weak 2025 Outlook

Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the consensus estimate of $15.49 billion. Excluding the impact of foreign exchange,

STAT8h

Merck’s earnings miss focused attention on Gardasil. The real issue is Keytruda

Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales of ...

FiercePharma15h

Merck halts Gardasil shipments to China, withdraws $11B sales target as demand nosedives

The continued decline of Merck & Co.’s HPV vaccine Gardasil in China has come to a head as the New Jersey drug giant is ...

BioSpace15h

Merck’s Gardasil Woes Grow as China Trade War Heats Up

Merck reported a 2% decline in Gardasil sales, after reaching a peak of $8.9 billion in 2023. Now with shipments to China paused, the HPV vaccine faces significant headwinds going into 2025.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

China, Merck and Gardasil

Trending now